adMare
News

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study.

adMare BioInnovations invites early-career science professionals to apply to the BioInnovation Scientist (BIS) Program: Foundations Cohort II

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.

Landmark Report Published on the Status of Inclusion, Diversity, Equity and Accessibility (IDEA) in Canada’s Life Sciences Sector

Abdera’s Success: adMare model of company creation 

CPDC Funds Research at Simon Fraser University for Developing
an LAT1-targeting Pet Tracer for Imaging Cancer
 

Applications Now Open for Cohort VI of the adMare Academy Executive Institute Program

Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023